# the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Diet and Exercise Alone

Study · id `cardio:ct-nct06650007` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06650007](<https://clinicaltrials.gov/study/NCT06650007>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06650007

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 218 participants.

## Technical summary

Registry record NCT06650007. Randomized; double masking; primary purpose treatment. Start 2024-11-08 (actual); primary completion 2026-01-21 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 218 participants (enrolled count; ClinicalTrials.gov record NCT06650007, source copy `cardio:ctgov-nct06650007-2026-07-14`, retrieved 2026-10-26)
- Started: 2024-11-08 (actual) (ClinicalTrials.gov record NCT06650007, source copy `cardio:ctgov-nct06650007-2026-07-14`, retrieved 2026-10-26)
- Primary completion: 2026-01-21 (actual) (ClinicalTrials.gov record NCT06650007, source copy `cardio:ctgov-nct06650007-2026-07-14`, retrieved 2026-10-26)
- Completion: 2026-06-12 (actual) (ClinicalTrials.gov record NCT06650007, source copy `cardio:ctgov-nct06650007-2026-07-14`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06650007, source copy `cardio:ctgov-nct06650007-2026-07-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06650007-2026-07-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Diet and Exercise Alone
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): HRS9531 Injection
- Intervention (Drug): HRS9531 Placebo Injection
- Lead sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. (`cardio:org-fujian-shengdi-pharmaceutical-co-ltd`)

## Provenance

Content hash: ed979640be845806a34c7e4f28d89d6a7c2a4b87958698e531cfa390f8821394
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
